CEL-SCI Corp CVM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
CEL-SCI’s Multikine® Receives Saudi FDA NADR Designation, Accelerating Potential Commercial Launch
CEL-SCI’s Dr. Eyal Talor Receives Second International Keynote Invitation on Multikine Head and Neck Cancer Research
CEL-SCI Presents New Phase 3 Multikine® Data at World Congress: Pre-Surgical Biomarkers Identify Head & Neck Cancer Patients Achieving 73% 5-Year Survival
CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology
Trading Information
- Previous Close Price
- $1.47
- Day Range
- $1.20–1.56
- 52-Week Range
- $0.90–7.79
- Bid/Ask
- $0.00 / $0.00
- Shares Outstanding
- 17.59M
- Market Cap
- $21.28M
- Volume/Avg
- 880,307 / 229,185
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 44
- Website
- https://www.cel-sci.com
Valuation
Metric | CVM |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.94 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | CVM |
|---|---|
Quick Ratio | 1.29 |
Current Ratio | 1.48 |
Interest Coverage | −50.13 |
Quick Ratio
CVM
Profitability
Metric | CVM |
|---|---|
Return on Assets (Normalized) | −91.46% |
Return on Equity (Normalized) | −194.44% |
Return on Invested Capital (Normalized) | −102.04% |
Return on Assets
CVM
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|pY%PK# | LOCK|pJ^cr | $131B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|gN%z>x! | LOCK|Glk&! | $95B | |||
| Moderna Inc MRNA | LOCK|c&^$xyD | LOCK|R^C | $79B | |||
| argenx SE ADR ARGX | LOCK|XgB>@r! | LOCK|Lh | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|gtZ<xd% | LOCK|F%S | $45B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|CJ<?P&! | LOCK|lw$?D | $30B | |||
| Incyte Corp INCY | LOCK|Dvk@&t | LOCK|fQG | $23B | |||
| BioNTech SE ADR BNTX | LOCK|%?#W@< | LOCK|D#X | $20B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|q>k>qS | LOCK|L%NJV | $19B | |||
| BridgeBio Pharma Inc BBIO | LOCK|!V@L&## | LOCK|Sy> | $15B |